• Fitzpatrick Skin Type of I to VI, targeting the following:

‣ Skin types I, II, III, or IV: 60-70% of enrolled subjects

⁃ Skin types V or VI: 30-40% of enrolled subjects

• Has acne as determined by PI and is undergoing current stable, daily treatment of acne for at least one month prior to study initiation.

• a. Treatments may include but are not limited to, either prescription or over-the counter products, such as: Benzoyl Peroxide, Retinoids (Adapalene, Tretinoin, Tazarotene), Topical Antibiotics and oral antibiotics (if used at least 30 days prior to Visit 1), Topical Dapsone, and Epiduo. Note: use of oral isotretinoin (Accutane) is prohibited. Targeting up to 20 subjects currently using a prescription treatment.

• Willing to continue his/her normal course of treatment (used at least 30 days prior to Visit 1), for their skin condition with no changes during the study.

• Generally, in good health based on medical history reported by the subject.

• Able to read, write, speak, and understand English

• Individuals have signed the ICD including the photo release and Health Insurance Portability and Accountability Act (HIPAA) disclosure

• Intends to complete the study and is willing and able to follow the subject responsibilities.